Bioelastomeric stent

• US 5,591,224 A
• Filed: 09/15/1994
• Issued: 01/07/1997
• Est. Priority Date: 03/19/1992
• Status: Expired due to Fees

• Current Assignee: Medtronic Incorporated (Medtronic Plc)
• Original Assignee: Medtronic Incorporated (Medtronic Plc)
• Inventors: Schwartz, Robert S., Wolff, Rodney G.
• Primary Examiner(s): BRITTINGHAM, DEBRA
• Application Number:
  US08/306,803
• Time in Patent Office: 845 Days
• Field of Search: 623/1, 623/11, 623/12, 606/191-200, 606/151-158, 600/36, 604/8, 604/104
• US Class Current: 623/1.22
• CPC Class Codes: A61F 2/0077 Special surfaces of prostheses, e.g. for improving ingrowth A61F2/30767 takes precedence
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2240/001 Designing or manufacturing processes
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/252 Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/622 Microcapsules
• CPC Class Codes: A61L 31/041 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 31/046 Fibrin; Fibrinogen
• CPC Class Codes: A61L 31/047 Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/128 containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 89/00 Compositions of proteins; Compositions of derivatives thereof foodstuff preparations A23J3/00
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device

Abstract

An bioelastomeric intraluminal stent comprising fibrin and elastin is capable of providing a treatment of restenosis.

Claims

1. A bioelastomeric intraluminal stent for implantation in a body lumen, the stent having an open-ended tubular shape defined by a structure comprising (a) elastin elements which are radially expandable to support the body lumen and (b) fibrin reinforced by elastin on a surface of the stent which is adapted to be retained in contact with a wall of the body lumen.

2. The stent of claim 1 wherein the fibrin is a fibrin in which residual coagulating protein has been neutralized to prevent clotting of blood in the body lumen.

3. The stent of claim 1 wherein the fibrin is in a film affixed to the elastin elements.

4. The stent of claim 1 wherein the stent comprises a formed mixture of fibrin and elastin.

5. The stent of claim 4 wherein the mixture also includes fibronectin.

6. The stent of claim 4 wherein the mixture also includes collagen.

7. The stent of claim 1 also comprising a catheter with a balloon at a distal end, the stent affixed to the outside surface of the balloon.

8. A bioelastomeric intraluminal stent for implantation in a body lumen, the stent having a framework formed in an open-ended tubular shape which is radially expandable to provide support for a body lumen and to retain the stent in contact with a wall of the body lumen at a lumen-contacting surface of the stent, the stent comprising fibrin and elastin reinforcing the fibrin on the lumen-contacting surface, the fibrin made from the reaction of fibrinogen with a coagulating protein.

9. The stent of claim 8 wherein the fibrin is a fibrin in which residual coagulating protein has been neutralized.

10. The stent of claim 8 wherein the stent also comprises fibronectin added into the fibrin.

11. The stent of claim 8 wherein the stent also comprises collagen in the fibrin.